Gritstone Bio Company Profile and Investor Insights

Gritstone Bio is a biotechnology company that focuses on developing cancer immunotherapies. Its research is based on neoantigen-specific T-cell priming technology.

Gritstone Bio was founded in 2015 by Andrew Allen and Matthew McKenna. The company's headquarters is located in South San Francisco, California.

Gritstone Bio's pipeline includes several clinical-stage programs, including GRANITE and SLATE, which are being tested for their ability to treat various types of cancer.

Gritstone bio has made significant progress in biotechnology and medical research. The company emerged from bankruptcy on April 4th, marking a crucial turning point in its journey.

The stock market has taken notice of Gritstone bio's developments, with a 5-day change of -90.00%. This significant fluctuation highlights the impact of the company's reorganization on investor confidence.

Gritstone bio's reorganization plan was approved on April 3rd, a major milestone in its recovery. This achievement demonstrates the company's commitment to its path forward.

Here's a summary of the key dates and market changes:

Gritstone bio's market capitalization has fluctuated significantly over time, ranging from 1.39M to 282M.

Some notable market capitalization values include 2.59M, 162M, and 282M.

The company's enterprise value has also changed, with a high of 4.18B and a low of 20.55M.

Gritstone bio's enterprise value to sales ratio for 2022 was 7.62x, while the 2023 ratio was 13.5x.

A free-float of 98.27% indicates that most of the company's outstanding shares are available for trading.

Here is a breakdown of Gritstone bio's enterprise value and market capitalization:

Gritstone bio has emerged from Chapter 11 bankruptcy and is now focused on developing its portfolio of BiSpecifics. This is a significant development for the company, which has been working on its lead candidate focused on CT83.

Gritstone bio has announced encouraging updated interim Phase 2 data from its ongoing Phase 2 study evaluating GRANITE, an individualized neoantigen targeting immunotherapy in patients with microsatellite stable colorectal cancer. This data shows GRANITE's ability to continue to mature and demonstrate durable benefit over time.

A unique perspective: Granite Broadcasting

Here are some key events that have led to Gritstone bio's current status:

Gritstone bio has also made changes to its leadership team, including the resignation of executives and the appointment of new CEOs. These changes may have contributed to the company's current focus on development and research.

Gritstone bio has filed several documents related to its bankruptcy and restructuring, including a Regulation FD Disclosure Form 8 K and a Bankruptcy Form 8 K. These documents provide further insight into the company's financial situation and its plans for the future.

Broaden your view: What Is Kyc Documents

Gritstone bio has secured funding from several notable investors, including PFM Health Sciences, Redmile Group, and Frazier Life Sciences.

These investors have participated in at least one funding round for Gritstone bio. In fact, PFM Health Sciences, Redmile Group, and Frazier Life Sciences are among the 6 institutional investors backing the company.

Here are the specific funding rounds involving these investors:

Gritstone bio, Inc. has a clear leadership structure in place, with Vassiliki Economides serving as the CEO since December 30, 2024, at the age of 45.

The company's Human Resources Officer, Stacy Lea Proctor, is responsible for overseeing HR-related matters, although her age and start date are not publicly disclosed.

James Cho, the Comptroller/Controller/Auditor, has been in this role since January 26, 2021, and his age is also not publicly available.

Here is a list of the key managers and directors at Gritstone bio, Inc.:

Gritstone bio has secured funding through two rounds. Its first funding round was on September 16, 2021.

Gritstone bio's latest funding round was a Grant (prize money) round on October 13, 2023, for $10M. This round was led by a single investor, HHS.

PFM Health Sciences, Redmile Group, Frazier Life Sciences, and Gilead are among the notable investors in Gritstone bio. The company has a total of 6 institutional investors.

Here's a breakdown of Gritstone bio's funding rounds:

Gritstone bio's funding rounds have significant post-money valuations. The 2021 round had a post-money valuation of $9,186,417, while the 2023 round had a post-money valuation of $3,562,594.

For more insights, see: Post-money Valuation

Analysts' Recommendations can be a crucial factor in making informed investment decisions. Analysts' opinions can significantly impact stock prices and investor confidence.

Gritstone bio, Inc. has received downgrades from several analysts in the past. B. Riley Downgrades Gritstone bio to Neutral From Buy with a $1 price target, while HC Wainwright Downgrades Gritstone bio to Neutral From Buy with a price target of $0.50.

Analysts have also adjusted their price targets for Gritstone bio. B. Riley Cuts Price Target on Gritstone bio to $3 From $6, and B. Riley Adjusts Gritstone bio's Price Target to $6 From $8.

Here's a summary of the downgrades and price target adjustments for Gritstone bio:

Analysts' opinions can be unpredictable, and it's essential to stay informed about the latest developments in the market.

Gritstone Bio, Inc. is the main legal entity associated with the company. It was incorporated on December 31, 2014.

The company is based in the United States and is currently active. Its CIN (Company Identification Number) is 474859534.

Gritstone Bio, Inc. has a significant employee base, with 231 employees as of December 31, 2023.

Gritstone bio has some notable competitors in the biopharmaceutical industry. One of its top competitors is Jazz Pharmaceuticals, a public company based in Dublin, Ireland, with a total funding of $265M.

Jazz Pharmaceuticals is a developer of novel biopharmaceutical medicines for unmet medical needs. This expertise puts it in a strong position to compete with Gritstone bio.

Another competitor is Moderna, a public company based in Cambridge, Massachusetts, with a total funding of $2.78B. Moderna is a developer of mRNA-based therapeutics for a wide range of diseases.

Moderna's large funding and expertise in mRNA-based therapeutics make it a significant competitor to Gritstone bio. This is reflected in their similar Tracxn scores of 81/100.

Here's a list of the top 5 competitors to Gritstone bio, ranked by their Tracxn score:

These competitors have significant funding and expertise in the biopharmaceutical industry, making them strong contenders to Gritstone bio.